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Abstract
Objective Elderly patients with malignant head-and-neck
tumors (HNT) often pose a therapeutic challenge. They fre-
quently have significant comorbidities which may influence
their ability to tolerate tumor-specific therapies. Our aim
was to investigate the outcome of patients aged 80+ years
undergoing curative intent intensity- or volume-modulated
radiation therapy (IMRT/VMAT).
Methods We retrospectively reviewed our HNT patients
aged 80+ treated with curative IMRT/VMAT from Decem-
ber 2003 to November 2015. Overall survival (OS), disease-
free survival (DFS), local control (LC), and treatment toler-
ance were assessed. Outcome results were compared with
that of a younger HNT patient cohort from our hospital.
Results A total of 140 consecutive patients were included
(65 postoperative, 75 definitive). Mean/median age at
treatment start was 84.8/84.1 years (range 80–96 years).
Mean/median follow-up time was 25/16 months (range
2–92 months). Of the 140 patients, 80 were alive with no
evidence of disease when last seen, 28 had died due to
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the cancer, 12 remained alive with disease, the remaining
20 died intercurrently. Systemic concomitant therapy was
administered in 7 %. Late grade 3–4 toxicity was observed
in 2 %. All patients completed treatment. Hospitalization
and feeding tube rates were 26 % and 11 %, respectively.
The 2-/3-year LC, DFS, and OS rates for the entire cohort
were 81/80 %, 69/63 %, and 68/66 %, respectively. Squa-
mous cell carcinoma (SCC) patients showed an inferior 3-
year OS rate as compared to non-SCC patients (62 % vs
77 %, p = 0.0002), while LC and DFS did not differ. Pa-
tients undergoing postoperative radiation attained a higher
OS compared to the definitively irradiated subgroup with
74 vs. 60 % at 3 years (p = 0.01); however, DFS rates were
similar for both groups (68 vs. 61 %, p = 0.15). Corre-
sponding rates for >1400 HNT patients <80 years treated
during the same time interval were 81/80 %, 69/67 %, and
77/72 %, respectively.
Conclusions Treatment tolerance in our patients aged 80+
was high. These results suggest that elderly HNT patients
should not be denied potentially curative treatment strate-
gies.
Keywords Elderly · Treatment outcome · Radiotherapy of
elderly patients · Survival analysis · Radiation tolerance
IMRT/VMAT zur Behandlung von Malignomen
im Kopf-Hals-Bereich
Outcome bei über 80-jährigen Patienten
Zusammenfassung
Ziele Das therapeutische Vorgehen bei betagten Patienten
mit Kopf-Hals-Tumoren (KHT) ist anspruchsvoll. Meist be-
steht eine relevante Komorbidität, was die Behandlungsto-
leranz beeinflussen kann. Ziel war es, Therapieerfolg und
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-toleranz unserer kurativ intensitäts- oder volumenmodu-
liert radiotherapierten (IMRT/VMAT) Patienten im Alter
von >80 Jahren zu evaluieren.
Methoden Zwischen Dezember 2003 und November 2015
an unserer Klinik kurativ IMRT/VMAT-behandelte KHT-
Patienten im Alter von >80 Jahren wurden retrospektiv ana-
lysiert. Gemessen wurden Gesamtüberleben (GÜ), krank-
heitsfreies Überleben (KFÜ), lokale Kontrolle (LK) und
Therapietoleranz. Die Daten wurden mit unserer jüngeren
Patienten-Kohorte verglichen.
Resultate Erfasst wurden 140 Patienten (65 postoperativ,
75 definitiv bestrahlt). Das mittlere/mediane Alter bei Be-
handlungsbeginn betrug 84,8/84,1 Jahre (80–96), die mittle-
re/mediane Verlaufsbeobachtungszeit 25/16 Monate (2–92).
Bei Letztkontakt waren von den 140 Patienten 80 Patienten
krankheitsfrei am Leben, 28 verstarben am Tumorleiden,
12 lebten mit Krankheitsmanifestationen, 20 verstarben in-
terkurrent. Eine systemische Therapie wurde in 7 % simul-
tan appliziert, Spättoxizität Grad 3–4 fand sich bei 2 %.
Alle Patienten konnten die Bestrahlung abschließen; die
Hospitalisierungs- bzw. Magensondenrate betrug 26 bzw.
11 %. Die 2-/3-Jahresraten für LK, KFÜ und GÜ lagen bei
81/80 %, 69/63 % und 68/66 %. Patienten mit Plattenepi-
thelkarzinomen (SCC) zeigten bei gleicher LK und KFÜ
ein niedrigeres GÜ als jene mit Non-SCC (62 vs. 77 %;
p =0,0002). Patienten nach postoperativer IMRT wiesen
ein höheres GÜ auf als jene nach definitiver IMRT (74 vs.
60 % nach 3 Jahren; p = 0,01); das KFÜ war jedoch ähn-
lich für beide Untergruppen (68 vs. 61 %; p = 0,15). Die
korrespondierenden Raten für unsere >1400 IMRT/VMAT-
KHT-Patienten <80 Jahren betrugen 81/80 %, 69/67 % und
77/72 %.
Fazit Die Behandlungstoleranz unserer Patienten im Al-
ter >80 war hoch. Dieses Ergebnis spricht dafür, betagten
Patienten ein potenziell kuratives Vorgehen nicht vorzuent-
halten.
Schlüsselwörter Betagte · Behandlungserfolg ·
Radiotherapie im Alter · Überlebenszeitanalyse ·
Strahlentoleranz
Introduction
Elderly patients with malignant head-and-neck tumors
(HNT) pose a therapeutic challenge. They are often in-
eligible for systemic therapy and participation in clinical
trials due to their advanced age and may have significant
comorbidities that influence their ability to tolerate tumor-
specific therapies. Other biological and social factors,
such as limited mobility and social supports, can further
impact the delivery of optimal oncological treatment. Ra-
diotherapy plays a pivotal role in the management of HNT,
particularly in those patients unable to undergo primary
surgical treatment. Chemotherapy may be combined with
radiation in cases of locally advanced disease with no
contraindications to systemic treatment; however, the role
of chemotherapy in elderly patients remains controversial
as the Meta-Analysis of Chemotherapy in Head and Neck
Cancer (MACH-NC) demonstrated a diminishing effect on
survival with increasing age [1].
HNT is typically a cancer of the elderly population and
U.S. data demonstrates that 47 % of mucosal HNT patients
diagnosed between 1973 and 2008 were aged greater than
65 years [2]. In Switzerland, the life expectancy for women
and men in 2009 was 84.4 years and 79.8 years, respec-
tively, one of the highest in the developed world. The per-
centage aged greater than 65 years was 17 % in 2009 and
is projected to reach 28 % by 2050 [3]. This projected in-
crease in the number of elderly patients will result in an in-
creased number of cancer diagnoses, as age is a known risk
factor for cancer development. Defining “elderly” remains
problematic and is often based on chronological age alone.
The National Institute on Aging and National Institutes of
Health have defined 3 categories: young old (65–74 years),
older old (75–85 years) and oldest old (>85 years) [4]. Al-
though such definitions are helpful to subdivide chronolog-
ical age, the impact of comorbidities, quality of life, and
functional status is not captured in such definitions. It is
prudent to consider and improve upon methods by which
elderly patients will be assessed for curative therapies [5]
and to determine the outcomes for treatment in order to
provide adequate and accurate information to patients.
The optimal radiotherapeutic management of elderly
HNT patients cannot be easily defined at present, due
to the paucity of randomized data, particularly of very
elderly patients. There is underrepresentation of the el-
derly in HNT clinical trials, where the age limit is often
restricted to 70–75 years [5]. Extrapolation of outcome
from pre-existing data from the 3-dimensional (3D) treat-
ment planning era should be undertaken with caution, as
contemporary management utilizes intensity-modulated
radiotherapy (IMRT) or volume-modulated arc therapy
(VMAT) which may confer a more advantageous toxicity
profile as demonstrated in clinical trials [6].
To evaluate our institutional experience, we assessed the
patterns of care, tumor control and treatment tolerance for
patients 80+ undergoing curative radiotherapy for mucosal
or nonmucosal HNT with IMRT or VMAT.
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Table 1 Treatment-related parameters
Parameters n (%)
IMRT/VMAT techniques 140 (100)
Definitive radiation 75 (54)
Postoperative radiation 65 (46)
Treatment schedules
30–33× 2 Gy = 60–66 Gy (postop) 59 (42)
33× 2.11 Gy = 69.6 Gy (definitive) 29 (21)
35× 2 Gy = 70 Gy (definitive) 22 (16)
34× 2 Gy = 68 Gy (definitive, 6
fractions per week)
10 (7)
30× 2.2 Gy = 66 Gy (definitive) 3 (2)
2.5–3.5 Gy/fraction to 39–56 Gy 17 (12)
Treatment delivery
Ambulatory 104 (74)
Inpatient 36 (26)
Systemic therapy 8/140 (5)
Carboplatin 1 (6 cycles)
Cetuximab 7 (5–7 cycles)
Feeding tube (hospitalization:
included in the 36 inpatients listed
above)
15 (11)
Materials and methods
Patient and treatment parameters
We retrospectively reviewed our HNT IMRT/VMAT
database to identify patients with mucosal or nonmu-
cosal HNT aged 80+ receiving curative radiotherapy from
December 2003 to November 2015. All patients were
initially discussed in our weekly interdisciplinary head and
neck tumor board. Two multimorbid patients selected for
curative radiation were excluded from this analysis: in one
patient, IMRT was prematurely interrupted (3 fractions of
2 Gy) due to a sacrum fracture following a fall; a second
patient developed cardiopulmonary decompensation fol-
lowing surgery prior to the start of radiation and did not
sufficiently recover to commence curative radiation (2 of
142 patients with intention to treat).
Patterns of care, including treatment modalities received
(surgery, radiotherapy, chemotherapy, immunotherapy) and
ambulant or inpatient treatment were evaluated. Further
patient, tumor and treatment characteristics were collected,
including age, ECOG performance status (PS) at the time of
initial radiation oncology consultation, radiotherapy dose,
and fractionation. For comparison reasons, we used out-
come data from our younger IMRT patients (<80 years)
that had been collected in our database. Approval from the
local ethics committee was obtained for data evaluation of
our IMRT/VMAT cohort.
Radiotherapy
Patients were immobilized in the supine position from the
vertex to shoulders with commercially available thermo-
plastic masks. Planning CT images of 2-mm slice thick-
ness were acquired from the supraorbital ridge or vertex
to the carina with iodinated contrast medium in all eligible
patients. Our approach to target volume definition has been
extensively outlined in a prior publication [7]. No specific
modifications of our planning target volume (PTV) con-
cepts were performed, except in a few patients with very
large gross tumor volume (GTV), whereby the GTV was
individually defined as PTV70 Gy, with a margin of ap-
proximately 0.5 to 1 cm defined as PTV68 Gy. These PTV
adjustments were also used in younger patients and were
thus independent of age.
Treatment plans were calculated using the Varian Treat-
ment Planning System (Eclipse* External Beam Planning
System, Version 7.3.10 and PRO 8.9, AAA 8.9, Varian
Medical Systems). An extended field simultaneous inte-
grated boost (SIB)-IMRT technique, whereby the primary
tumor and regional lymph nodes are covered in a single
phase by a 6-MV dynamic MLC system (Varian Medical
Systems, Palo Alto, CA, USA) using a sliding window
technique, or alternatively a VMAT technique, was used
[7]. Our internal standard radiotherapy schedules were used
(Table 1).
Systemic concomitant therapy
Carboplatin was administered at AUC 2 when combined
with radiotherapy. Adjuvant chemotherapy consisted of
carboplatin AUC 5 and 5-fluorouracil (5-FU) 1000 mg/m2
(6 cycles) and was given to one patient. Cetuximab was
administered at standard doses of 400 mg/m2 loading dose,
followed by 250 mg/m2 weekly during the course of radio-
therapy. No cisplatin-based systemic therapy was given in
this elderly patient subgroup.
Follow-up
Patients were seen weekly during the course of radiother-
apy, or more frequently as required. Weekly clinical re-
views in the Department of Radiation Oncology were con-
tinued until the acute treatment toxicities had significantly
improved or resolved. Patients were reviewed 4–6 weeks
after completion of radiotherapy in our joint clinics at the
Department of Head and Neck or at the Department of Max-
illofacial Surgery. Our standardized follow-up program has
been reported in prior publications [7], although frequency
of follow-up was reduced in some patients in the current
cohort due to age, limited mobility, or significant comorbid
factors.
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Table 2 Patient and tumor characteristics
Parameters n (%)
Patients 140
Gender 46 women : 94 men
Follow-up, mean/median (range) 25/16 months (2–92)
Age mean/median (range) 84.8/84.1 years (80–96)
80–85 years 85 (61)
>85–90 years 36 (26)
>90 years 19 (13)
Pre-IMRT performance status
0 82 (59)
1 41 (29)
2 12 (9)
3 5 (3)
Histology
Squamous cell carcinoma 93 (66)
Spinocellular carcinoma 17 (12)
Melanoma 7 (5)
Thyroid carcinoma 5 (3)
Merkel cell carcinoma 4 (3)
Non-Hodgkin lymphoma (NHL) 4 (3)
Basal cell carcinoma 2 (1)
Others 8 (5)
Diagnosis
Oral cavity 24 (18)
Skin 24 (18)
Oropharynx 21 (15)
Larynx 20 (14)
Hypopharynx 10 (7)
Salivary glands 10 (7)
Nose 7 (5)
Paranasal sinus 6 (4)
Thyroid 6 (4)
Unknown primary tumor 5 (3)
Non-Hodgkin lymphoma (NHL)
Others 4 (3)
T stages (without NHL)
r0 11 (8)
1 11 (8)
2 31 (22)
3 17 (12)
4 37 (26)
Recurrence 23 (16)
N stages (without NHL)
0 (N0/rN0) 65 (46%) (59/6)
1 18 (13)
2a 5 (3)
2b 25 (18)
2c 11 (8)
3 4 (3)
Recurrence 8 (5)
Outcome
Tumor control was assessed in terms of overall survival
(OS), disease-free survival (DFS), and local control (LC).
Treatment tolerance: Hospitalization was defined as any
admission to hospital during radiotherapy treatment. Place-
ment of a feeding tube is routinely performed as an inpatient
at our center and these patients were therefore included in
the hospitalized group. Acute toxicity was not documented
in detail in all patients; however, the need for hospital-
ization and the duration of radiation therapy (total treat-
ment time vs. scheduled treatment time) were considered
surrogate parameters for early treatment tolerance. Worst
grade of late toxicity was scored according to the Radiation
Therapy Oncology Group (RTOG)/European Organization
for Research and Treatment of Cancer (EORTC) radiation
morbidity criteria.
Detailed treatment toxicity data were not analyzed for the
younger IMRT cohort in the statistical analysis; therefore,
no comparison was performed with the elderly cohort.
Statistics
Kaplan–Meier survival curves were performed using the
StatView® (Version 4.5) statistics program. P values <0.05
were considered statistically significant.
Results
Patient and tumor characteristics
A total of 140 patients aged 80+ years out of 1606 (9 %)
consecutively curatively treated patients with mucosal
(98/140) and nonmucosal HNT were identified from our
database and included in this analysis (Table 2). All patients
had mucosal tissue included in the planning target volume.
Mean/median age at treatment start was 84.8/84.1 years
(range 80–96 years). Mean/median follow-up time was
25/16 months (range 2–92 months).
More than 60 % of all patients presented with advanced
T3/4, and/or N2c/N3, or recurrent disease after previous
surgery alone.
Data from our younger IMRT cohort aged <80 years was
evaluated and compared with the elderly group. Squamous
cell cancer (SCC) was diagnosed in 66 % of the elderly ver-
sus 84 % of the younger patients. Both the >80 and <80 year
subgroups showed approximately 50 % T3/4 primary stage
tumors, while the advanced nodal status (N2c/N3) was 20 %
for younger patients and 11 % for the older cohort. IMRT
was postoperatively delivered in 46 and 41 % of patients
aged >80 and <80 years, respectively.
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Fig. 1 Disease control. LC local control, DFS disease-free survival,
OS overall survival
Fig. 2 Disease-free survival related to age intervals. y years, Cum.
Survival cumulative survival
Fig. 3 Overall survival rates related to age intervals. y years, Cum.
Survival cumulative survival
Treatment tolerance
Of 140 patients, 36 (26 %) required part or all of their
treatment as an inpatient (Table 1). A total of 15 (11 %)
patients required a feeding tube during treatment, including
1 patient who received the tube prior to commencement of
radiotherapy. The need for a feeding tube was not related
to WHO PS (10 tubes in 82 PS 0 patients, 4 in 41 PS
1 patients and 1 in 17 PS 2 patients). The need for a feeding
tube was inversely related to the age intervals: no tube was
required in 19 patients >90 years, 7 tubes in 36 patients
aged 85–90 years, 8 tubes in 85 patients aged 80–85 years.
All patients were able to complete treatment. Total treat-
ment times were maintained according to the initial sched-
ule in 136 of 140 patients (74 %); 4 patients had a treatment
delay between 5 and 11 days. Late grade 3 and 4 toxic-
ity was observed in 3 patients (1 patient with grade 2–3
osteoradionecrosis following tooth extraction post IMRT;
1 patient required a persisting feeding tube; 1 patient with
grade 2–3 xerostomia).
Disease control
The 2-/3-year LC, DFS, and OS rates for the entire 80+ co-
hort were 81/80 , 69/63, and 68/66 %, respectively (Fig. 1).
The corresponding survival rates for >1400 HNT IMRT pa-
tients aged <80 years (mean/median 60.9/62.7 years, range
16–79.8 years) and treated during the same time interval
(with additional simultaneous systemic therapy in 71 %) at
our center were 81/80 % (NS), 69/67 % (NS), and 77/72 %
(p <0.001), respectively. DFS (Fig. 2) and LC rates (data
not shown) of the 80+ cohort were comparable to our
younger IMRT HNT patients; OS was inferior in the 80+
cohort (Fig. 3). Ambulatory elderly patients showed higher
3-year OS than inpatients (approximately 70 vs approxi-
mately 50 %, p = 0.006). In addition, 80+ patients with
pre-IMRT WHO performance status (PS) 0–1 demonstrated
higher 3-year OS than patients with PS 2–3 (approximately
70 vs approximately 40 %, p = 0.01). Gender did not im-
pact on OS (p = 0.7) or DFS (p = 0.5). In addition, the need
for a feeding tube did not result in any significant differ-
ence in OS (p = 0.8); however, the sample size of patients
was unbalanced (n = 15 vs. 135 with and without a feed-
ing tube, respectively). Patients undergoing postoperative
radiation attained a higher OS compared to the definitively
irradiated subgroup (fit enough for surgery and/or smaller
tumors), with 74 vs. 60 % at 3 years (p = 0.01); however,
DFS rates were similar for both groups (68 vs. 61 %, p =
0.15). SCC patients showed an inferior 3-year OS rate as
compared to non-SCC patients (62 vs. 77 %, p = 0.0002),
while LC and DFS did not differ (NS).
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Discussion
We were motivated to determine the outcomes and treat-
ment tolerance of very elderly patients with HNT treated
with modern radiotherapy techniques. As this subgroup ac-
counts for approximately 10 % of all patients referred for
curative or postoperative IMRT or VMAT to our center,
knowledge regarding tumor control and side effects is cru-
cial. We chose an arbitrary age of 80+ years, as this was
an age whereby treatment decisions were often challenging
for our interdisciplinary team.
This is, to our knowledge, the largest published group of
“older and oldest old” HNT patients treated with modern
radiation techniques (Table 3; [8–15]). We found DFS and
LC rates (data not shown) comparable to that of younger
patients, and a high treatment tolerance. Treatment deci-
sions made at our weekly interdisciplinary head and neck
cancer center tumor board represent a selection process in
favor of fitter patients, as patients considered too ill or non-
compliant to undergo treatment with potentially substantial
side effects were not selected for curative radiation. Re-
garding the decision for (or against) treatment, we could
not draw any reliable decision-making assistance from the
initial WHO PS or the need for a feeding tube.
One of the limitations of our study was the inclusion
of patients with nonmucosal sites. We acknowledge that
treatment tolerance may be different in this group as less
mucosa may have been included in the radiation field; how-
ever, the radiation dose applied was very similar. Patients
treated for NHL (3 %) received significantly lower doses
than mucosal HNT, but comprised a very small number of
our cohort. Patients with spinocellular carcinoma under-
went extensive lymphatic pathway irradiation and were not
at substantially lower risk for side effects than patients with,
for example, early stage laryngeal carcinoma. We included
7 patients with nasal tumors (including nasal mucosa only)
as a dose of 70 Gy to the nose is not easy to tolerate at any
age, which was our rationale for including these patients
in our elderly cohort. As the aim of this analysis was to
evaluate whether irradiating elderly HNT patients with cu-
rative intent is beneficial compared to its potential risk, we
included all patients irrespective of mucosal or nonmucosal
tumor origin.
We also included postoperatively irradiated patients, as
the question of the benefit–risk ratio of postoperative radi-
ation therapy is often difficult to decide in elderly patients.
Although these patients are exposed to a somewhat lower
radiation dose, they underwent and survived a surgical pro-
cedure; conversely, patients not fit enough for surgery re-
ceive a higher radiation dose and are, thus, exposed to other
potential risks. The risk level of the two approaches are dif-
ficult to compare and may be dependent on the individual
patient, their comorbidities, their treatment wishes, or the
potential treatment bias of the treating physicians.
The study was also limited by the retrospective nature of
the analysis. The limited follow-up of our patients can also
be attributed to their age and other comorbid or social prob-
lems, which prevented their attendance for ongoing follow-
up.
The total number of patients with theoretically curable
malignant HNT who were not selected for curative treat-
ment is not available to us, however is estimated to be low
(<5 patients/year). In addition, having a diagnosis of can-
cer at an advanced age and being an older individual who
is well enough to attend for a specialist consultation, may
already represent a substantial positive preselection for cu-
rative treatment.
Consistent with our own cohort, many of the published
series confirm a high rate of treatment completion in the el-
derly population (approximately 90–100 %) suggesting that
patients either tolerate treatment well and/or were well se-
lected to receive curative therapy. Data from a prospective
study from Pignon et al. [10] noted similar rates of OS and
locoregional control in patients less than or greater than
70 years. This could be confirmed by our results (Fig. 3),
showing very similar OS rates for patients <70 and 70–80
years. Some of the published series show 5-year OS rates of
20–30 %, reflecting the influence of reduced life expectancy
in this group and the competing risk from comorbid condi-
tions. Our data demonstrate improved 3-year OS outcomes
in comparison to the published data: approximately 70 %
for patients less than 80 years, approximately 50 % for the
subgroup 80+ (Fig. 3). We found only three further reports
assessing patients 80+ (Zachariah et al., n = 35 [11], Mit-
suhashi et al., n = 11 [12], Schofield et al., n = 98 [14]),
therefore, limiting data comparison (Table 3).
There have been an increasing number of publications
assessing the tolerance and outcome of radiochemotherapy
regimens in elderly patients (Table 4; [16–23]). Nguyen
et al. [21] evaluated the toxicity and outcomes of various
chemotherapy regimens combined with modern radiother-
apy techniques in patients aged younger and older than
70 years. They demonstrated no significant difference in
grade 3 or 4 toxicity between the two groups and simi-
lar rates of tumor control. Machtay et al. [17] undertook
a retrospective analysis of RTOG trial data with a focus on
late toxicity. They demonstrated a significant increase in
late severe toxicity for elderly patients, although there were
only 27 patients aged greater than 70 included in these
three studies. When combined with the subgroup analy-
sis finding of decreasing effect of chemotherapy with age
in the MACH-NC meta-analysis of chemoradiation trials,
one needs to proceed with caution when offering combined
modality therapy to elderly patients [1]. In our cohort, one
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Table 3 Radiotherapy only studies in elderly head-and-neck tumor (HNT) patients
Author,
year [ref]
Treatment
interval
Study type Patient
(No.)
Age
(years)
Dose/
schedule
Technique Outcome Toxicity Comple-
tion rate
Lusinchi
et al.,
1990
[8]
1978–1983 Retrospective
single
institution
331
(277
cura-
tive)
>70 65–75 Gy
in 2 Gy 5x/
week or
2.5 Gy 4x/
week
Non-IMRT 71 % LC
in curative
intent arm
5-year
21 and
0 % for
age 80–85
and over
84 years
Acute: severe
epithelitis 1 %,
Severe mu-
cositis 17 %
Late: mucosal
necrosis 3.6 %
Osteonecrosis
2.1 %, Laryn-
geal dyspnoea
2.7 %
91 %
curative
Huguenin
et al.,
1996
[9]
1996 Retrospective
single
institution
75 ≥75 70 Gy in
1.8–2 Gy
74.4 Gy in
1.2 Gy 2x
day
3D CRT 5-year OS
30 %
2-year LC
83 % T1–2
N0, 39 %
for advanced
disease
Acute: NA
Late: 1 bone
necrosis
92 %
Pignon
et al.,
1996
[10]
1980–1995 Prospective
EORTC
trial
database
1589 20–82
12 %
>70
4 trials com-
pared con-
ventional
fractionation
to multifrac-
tionation; 1
trial com-
pared CT
plus surgery
and RT to
surgery and
RT alone
Non-IMRT No differ-
ence in OS
or LRC Be-
tween age
groups
Acute: func-
tional mucosal
reaction G3
and G4 more
frequent in
older ages, ef-
fect no longer
significant
when PS was
controlled for
Late: no dif-
ference be-
tween age
groups
NA
Zachariah
et al.,
1997
[11]
1988–1995 Retrospective,
2 institu-
tions
35 (in-
cluded
brain
and
upper
aerodi-
gestive
tract
tu-
mors)
≥80 50–77.8 Gy
in 1.1–2.5 Gy
Non-IMRT CR 66 % Acute: 1 G4
mucositis
Late: NA
NA
Mitsuhashi
et al.,
1999
[12]
1970–1997 Retrospective
single
institution
14
(11/14
cura-
tive)
≥90 Median cu-
rative dose
61.2 Gy
(35–78)
Conventional
EBRT
RR 90 %
CR 60 %
Acute:
G3–4 mucosi-
tis 40 %
Late:
NA
91 %
(curative
cases)
Allal
et al.,
2000
[13]
1991–1997 Retrospective
single
institution
39 ≥70 69.9 Gy in
41f over
38 days
Non-IMRT 3-year OS
68 %
3-year LRC
73 %
Acute: G3
64 %
G4 2.6 %
Late:
RTOG G3–4
toxicity 3 %
100 %
Schofield
et al.,
2003
[14]
1991–1995 Retrospective
single
institution
98 ≥80 50–55 Gy/16f
45–47.5 Gy/16f
Non-IMRT
Beam
directed
technique
5-year OS
28 %
5-year CSS
59 %
5-year LC
70 %
Acute: NA
Late:1 os-
teo-ra-
dionecrosis
1 oro-antral
fistula
1 laryngeal
perichondritis
98 %
K
Strahlenther Onkol (2016) 192:526–536 533
Table 3 Radiotherapy only studies in elderly head-and-neck tumor (HNT) patients (Continued)
Author,
year [ref]
Treatment
interval
Study type Patient
(No.)
Age
(years)
Dose/
schedule
Technique Outcome Toxicity Comple-
tion rate
Huang
et al.,
2011
[15]
2003–2007 Retrospective
single
institution
238 ≥75 (7
≥80y)
51 Gy/20f
60 Gy/25f
64 Gy/40 f,
2f/day
70 Gy/35 f,
CRT
70 Gy/35 f,
RT
Other
Conformal
or IMRT
1-year CSS
83 %
2-year CSS
71.7 %
5-year CSS
64.9 %
5.9 % ≥ G3
RTOG toxicity
96 %
Own
data,
2016
2003–2015 Retrospective
single
institution
140 ≥80 70 Gy/33–35f
66 Gy/33f
60 Gy/30f
other
IMRT or
VMAT
3-year LC
80 %
3-year DFS
63 %
3-year DFS
66 %
3 % G3 (1x
Osteo-ra-
dionecrosis,
1x xerostomia,
1x feeding
tube depen-
dence)
100 %
NA not available, LC local control, OS overall survival, CR complete response, RR response rate, CSS cause-specific survival, PS performance
status, G Grade, RTOG Radiation Therapy Oncology Group, EORTC European Organisation for the Research and Treatment of Cancer, f fractions
very fit and motivated patient received chemotherapy, which
was an exceptional case.
Immunotherapy is considered a viable option for those
patients unable to receive systemic chemotherapy. We iden-
tified 7 of 140 patients who received between 5–7 cycles of
concomitant cetuximab therapy in our patient cohort. The
recent update of the Bonner et al. [24] study demonstrated
on subgroup analysis that cetuximab had no benefit in pa-
tients aged 65 years or older; however, this analysis was
underpowered due to small patient numbers aged greater
than 65 years and age was not a study endpoint. Alongi
et al. [25] reported on a phase II study in elderly patients
utilizing cetuximab in combination with IMRT-SIB, which
confirmed rates of toxicity consistent with the Bonner data
[24].
A randomized controlled trial is currently assessing the
impact of comprehensive geriatric assessment (CGA) on
survival, function, and nutritional status in elderly HNC pa-
tients receiving standard care [26]. Whether these tools will
impact on the appropriate selection of patients for curative
radiotherapy is not yet known. Clearly there is a growing
need for further research in the elderly oncological pop-
ulation. The International Society of Geriatric Oncology
is addressing these issues and has undertaken a review of
current best practice and priorities for research in radiation
oncology for elderly patients [27].
Conclusions
Treatment tolerance in our patient cohort aged 80+ was
high. Local and disease-free survival rates were similar to
that of younger HNT patients treated at our center. These
results suggest that very elderly patients should be consid-
ered for potentially curative treatment strategies.
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Table 4 Radiochemotherapy studies in elderly patients with head-and-neck tumor
Author,
year
[ref]
Date of
treat-
ment
Study type Patient
(No.)
Age Dose Chemotherapy
type
Technique Outcome Toxicity Completion
rate
Kodaira
et al.,
2005
[16]
NA Phase 1
prospec-
tive
11 ≥70 60–70 Gy/
30–35f or
39.6 Gy
in 1.8Gyf
re-RT
Weekly
docetaxel,
starting
dose
10 mg/m2,
additional
increase of
2 mg/m2
up to max-
imum
tolerated
dose al-
lowed
3D or
dynamic
rotation
See
toxicity
data
Acute: No
G3 or higher
hemtatologi-
cal toxicity
G3 mucositis
in 6 pts, G4
in 3 pts
Late: NA
NA
Machtay
et al.,
2008
[17]
1991–2001 Retrospective
secondary
analysis
of RTOG
trial late
toxicity
data
230 ≤70
and
>70
(n =
27)
Refer to following proto-
cols:
RTOG 91–11
RTOG 97–03
RTOG 99–14
Mostly
2D plan-
ning, no
IMRT
See
toxicity
data
Acute: NA
Late: Crude
rate of late
toxicity 43 %.
Older patients
significantly
more likely to
have severe
late toxicity
NA
Koussis
et al.,
2008
[18]
1999–2002 Prospective
phase II
(included
pat. with
esophageal
cancer)
35 ≥70
(16
el-
derly)
70 Gy/35f Neoadjuvant
carbo-
platin and
vinorel-
bine +
concurrent
carbo-
platin
No
IMRT
3D con-
formal
2-year
OS
41.5 %
Acute: 8.5 %
grade 4 mu-
cositis with
febrile neu-
tropenia
Late:1 osteo-
radionecrosis
100 % for
radiotherapy
and concurrent
carboplatin
Tsukuda
et al.,
2009
[19]
2002–2007 Prospective
feasibility
study
50 13
>75
66–70.2 Gy
in
1.8–2 Gy
2 courses
of S-1
with RT
– 50 or
40 mg bd,
2 weeks
on, 1 week
off
NA 2-year
DSS
92 %,
2-year
OS
75 %
Stage III
and
38 and
29 %
Stage IV
Acute: 18 %
grade 3
hematolog-
ical, 28 %
nonhemato-
logical
No grade 4
toxicity
Late: NA
100 % for
RT, 72 % for
S1-administration
Boscolo-
Rizzo
et al.,
2011
[20]
2000–2007 Prospective
single
institution
44 >65 66–70 Gy/
33–35f
IC
cisplatin
100 mg/m2
day 1,
5-FU
1000 mg/m2
for 5 days
Concurrent
cisplatin
100 mg/m2
day
1/5-FU
1000 mg/m2
for 5 days
week 1
and 4
3D con-
formal
3-year
LRC
76.5 %
3-year
PFS
67 %
3-year
OS
70.9 %
Acute:
65.9 %
G3–4 toxi-
city (G3–4
mucositis
34.1 %)
Late: 29.5 %
≥Grade 3 late
toxicity (3pts
permanent
tracheotomy,
4 permanent
PEG)
84.1 % per
protocol
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Table 4 Radiochemotherapy studies in elderly patients with head-and-neck tumor (Continued)
Author,
year
[ref]
Date of
treat-
ment
Study type Patient
(No.)
Age Dose Chemotherapy
type
Technique Outcome Toxicity Completion
rate
Nguyen
et al.,
2012
[21]
2008–2011 Retrospective
single
institution
112,
27
≥70
years
<70,
≥70
70 Gy/35f
66 Gy/33f
Cisplatin
weeks
1,4,7
Carbo
weekly
Cisplatin
weekly
Carbo
week 1,4,
7
5-FU and
cisplatin
Taxol
IMRT or
IGRT
2-year
OS
74 and
67.5 %
for <70
and
≥70
respec-
tively
Acute:
59.2 % G3–4
mucositis,
25.9 % G3–4
hematolog-
ical toxicity
in elderly. No
significant
difference
in G3–4 be-
tween young
and elderly
groups
Late:
16 %
younger, NA
for elderly
92 % <70
96 % ≥70
1 elderly pa-
tient due to
death in week
1 of RT (fall)
Merlano
et al.,
2012
[22]
1997–2008 Retrospective
single
institution
317,
224
<65
93
≥65
<65,
≥65
66–70 Gy/
33–35f
Adjuvant
concur-
rent cis-
platin/RT
Alternating
CTRT
Induction
CT and
CTRT
cetuximab
and RT
3D con-
formal
Younger
patients
have
signifi-
cantly
longer
survival
than
elderly
Elderly pa-
tients suf-
fered from
infections,
in particular
pneumo-
nia, more
frequently
than young
patients; no
difference in
other toxici-
ties
92 % <65
87 % ≥65
(p = 0.20)
Michal
et al.,
2012
[23]
1989–2007 Retrospective
single
institution
181,
137
<70,
44
≥70
<70,
≥70
68–74 Gy/
1.8–2 Gy
or
72–74.4 Gy/
1.2 Gy 2x
day
5-FU and
cisplatin
weeks 1
and 4 plus
gefitinib
for those
in a clini-
cal study
Non-IMRT 5-year
OS
63 vs
49 %
and
5-year
DSS
74 and
71 % in
<70 vs.
≥70
More un-
planned hos-
pitalizations
(84 vs. 67 %)
and feeding
tubes (89 vs.
69 %) in ≥70
NA
NA not available, f fractions, re-RT re-irradiation, RT radiotherapy, IC induction chemotherapy, G1–4 grade 1–4, OS overall survival, DSS dis-
ease-specific survival, LC local control, LRC locoregional control, 5-FU 5-fluorouracil
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